Aspen Neuroscience’s CEO, Damien McDevitt, PhD, was featured in Biocom California’s article, “A Look at the Year Ahead for Life Sciences.”
Damien states, “The lack of treatment options for patients with neurodegenerative diseases remains a significant unmet medical need, especially options that slow down or cure the underlying disease pathogenesis. The development of cell therapy replacement approaches, in particular, those using autologous induced pluripotent stem cells (iPSCs) has opened up an exciting field, with potential for many different types of diseases. Aspen Neuroscience is a leader in autologous (cells from the same patients) iPSC discovery, leveraging advanced cell biology, manufacturing, and genomic/bioinformatics quality control technologies to characterize and develop the highest quality cell therapies. In the coming year, we are encouraged by several autologous iPSC-based cell therapies entering clinical development, including our lead program addressing Parkinson’s disease. We hope to replicate the remarkable success with CAR-T therapies for patients with Parkinson’s and other neurodegenerative diseases.”
The article can be found here: https://www.biocom.org/lifelines/interviews/a-look-at-the-year-ahead-for-life-sciences/